Clinical Trial Detail

NCT ID NCT04055844
Title Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications

myeloid sarcoma

myelodysplastic/myeloproliferative neoplasm

acute myeloid leukemia

myelodysplastic syndrome

Therapies

Decitabine + Ruxolitinib

Age Groups: senior child adult

No variant requirements are available.